



## **A closer look**

abbvie

# AbbVie: An introduction

We're a biopharmaceutical company.

We're guided by people, powered by passion  
and in awe of the possibilities ahead of us.

We're highly focused, research-oriented and  
patient-centric.

We are AbbVie.



abbvie



# Our Principles

Our purpose is profound, and our path is clear. We embrace the responsibility of making a remarkable impact on people's lives through the innovative medicines and solutions we create together. This is driven by our compassion for people, commitment to innovation and inclusion, service to the community, and uncompromising integrity at the heart of everything we do.

Operating as one AbbVie team, we care deeply for our patients, their families, our employees, and our communities. We strive to always do the right thing, pursuing the highest standards in quality, compliance, safety, and performance. In everything we do, we invest and innovate relentlessly to tackle unmet needs, creating new medicines and healthcare approaches for a healthier world.

Globally, our employees embrace diverse backgrounds and perspectives and treat everyone equally, with dignity and respect, allowing us all to achieve our best. We proudly do our part to serve and support our communities and protect the environment, making a lasting impact that's felt within healthcare and beyond.

What we do isn't easy, but we persevere because what we achieve inspires hope and transforms lives – every single day.

**Transforming  
Lives**

**Acting with  
Integrity**

**Driving  
Innovation**

**Embracing  
Diversity &  
Inclusion**

**Serving the  
Community**

# A compelling growth story



2013

On January 2, 2013, we rang the opening bell on the New York Stock Exchange to mark our first official day as a new biopharmaceutical company




2014

AbbVie brands surpass 30 million patients impacted around the world and our first AbbVie-created medicine is approved.



2015

New treatment approvals for diseases like Parkinson's and hidradenitis suppurativa in 2015 were brought forward. We brought Pharmacyclics into the AbbVie family and expanded our commitment to identifying novel treatments for cancer.



2016

While earning new approvals in oncology and leading the biotech industry in the Dow Jones Sustainability Worldwide Index, we also expanded our neuroscience research – including Alzheimer's disease – with the opening of our 43,000-square-foot Cambridge Research Center in Massachusetts' biotech corridor.



2017

We expanded our operational capabilities and announced positive data on new investigational compounds in our immunology portfolio. With a growing pipeline, we prepared for a bright and busy future. We closed the year with the #2 spot on Barron's 500.



2018

We continued to introduce important new therapies for patients with approval of a treatment for women suffering with moderate to severe endometriosis pain. We exemplified our culture of giving back, donating \$350 million to support U.S. nonprofits. For the first time, we were recognized as a FORTUNE 100 Best Company to Work For.

# Impact on **patients**

abbvie

# Treating people

In 2018, AbbVie medicines helped



Over  
**30m+**  
patients



In more than  
**175+**  
countries



Treating over  
**32+**  
conditions

# Patient-driven health outcomes

## We go beyond medicine

to deliver innovative, holistic health care solutions to patients

Patient support programs in 2018

**292** Patient  
support programs  
globally

**90**  
Programs in the  
U.S.



Access to medicine in 2018

More than  
**81,000**  
U.S. patients  
received medicine  
at no cost





# Impact on science

abbvie



# Investing in science

At AbbVie, we have the commitment, expertise, and capabilities to provide life-changing products to patients who need them most



**~9,000**

employees in R&D today



**\$5.1bn**

Into research and development in 2018

abbvie

# Investing in science



**1,130**

papers  
published by  
our scientific  
community



**104k+**

Patients participated in clinical trials  
globally

---

**40k+**

Patients in the U.S.



## Partnerships & collaboration

Through collaboration, we advance science and innovation, the lifeblood of our company.

Partners include more than

**220**

Leading biotechs, universities, nonprofits and government organizations.

# **We're a company that takes on the toughest health challenges.**

We are relentless because we know patients, loved ones, healthcare professionals and caregivers are waiting. We are driven by a passion to make remarkable impact.



abbvie



# Therapeutic areas of focus

## Immunology

AbbVie is the leader in immunology.

We have been **leveraging deep scientific expertise to develop next-generation biologics and small molecules** in rheumatology, dermatology and gastroenterology



AbbVie medicine in immunology currently treats

**+1 million patients**

in **15** indications worldwide

**>20 new molecules**

under investigation

abbvie



# Therapeutic areas of focus

## Oncology

Oncology is one of our fastest growing therapeutic areas. We have treatments approved for multiple blood cancers:

**Acute Myeloid Leukemia**

**Chronic Graft vs Host Disease**

**Chronic Lymphocytic Leukemia**

**Mantle Cell Lymphoma**

**Marginal Zone Lymphoma**

**Waldenstrom's Macroglobulinemia**

Future areas of focus:

**Immuno-oncology**

**Apoptosis/B-cell receptor field**

**Antibody drug conjugates**



**200**

active oncology  
clinical trials in

**20+**

different types  
of cancers

abbvie


# Therapeutic areas of focus

## Neuroscience

We're researching and developing new, innovative, disease-modifying solutions to address some of the most difficult-to-treat degenerative diseases.

At our Cambridge Research Center and around the world, we're leveraging scientific breakthroughs of the last five to ten years, along with new biomarker tools like PET and MRI imaging, with the goal of developing medicines that slow, halt and ultimately reverse the damage of debilitating neurological diseases.

abbvie



# Therapeutic areas of focus

## Virology

AbbVie is focused on providing a competitive high-value treatment option for Hepatitis C virus (HCV).

- We continuously work with our partners in the healthcare systems to ensure patients are able to access treatments that bring value to them and the healthcare systems.
- We are working with regulatory bodies around the world to bring our pan-genotypic regimen to the majority of people living with HCV.

Despite the availability of a cure, the majority of people with HCV are untreated and in the earlier stages of liver disease.

Together with the HCV community, AbbVie is a committed member of the global movement towards HCV elimination with the goal to eliminate hepatitis C by 2030.





# Targeted investment: women's health

At AbbVie, we're applying our significant resources toward breakthroughs in areas that make a difference for women.

Focused investments in areas that fit our core strengths include:

- Endometriosis
- Uterine fibroids



# Impact on society



abbvie

We leverage our expertise and time. We look for ways to engage our best scientists to join the battle against neglected diseases.

**In 2018:**

More than

**1 billion**

of the world's population  
suffers from neglected  
tropical diseases (NTDs)

**400+**

AbbVie scientists  
contributed



**~40,000**

hours of expertise  
to help solve  
neglected diseases

# Commitment to the community

We're working with partners in transforming education to narrow the achievement gap in science and literacy

AbbVie Foundation donated

**500,000**

Books to U.S. children and schools

**37,000+**

Hours of service volunteered in our communities during our **Week of Possibilities**







# Our commitment to the environment is global

We've reduced water consumption at our **North Chicago** manufacturing site by over 400,000 m3 per year since 2015.

In **Japan**, 100% of fleet vehicles have been converted to hybrid.

Our **Campoverde, Italy** manufacturing site achieved an 84% recycling rate in 2018 including recycling solvents used in the active pharmaceutical ingredient manufacturing process.

We've installed rainwater harvesting equipment at our **Singapore** manufacturing site.

We purchase 100% renewable electricity at our manufacturing sites in **Europe** and are exploring opportunities to expand.

# External Recognition As a Top Company



## Workplace & Diversity

DiversityInc. “Top 50 Companies for Diversity”

---

FORTUNE “100 Best Companies to Work For”

---

Great Places to Work “World’s Best Workplaces”

---

Human Rights Campaign Corporate Equality Index

---

Science Magazine’s Top Employers

---

Working Mother “100 Best Companies”

---



## Corporate Responsibility

Civic 50

---

Corporate Responsibility Magazine’s “100 Best Corporate Citizens”

---

Dow Jones Sustainability World Index

---

FORTUNE/Great Places to Work “Best Workplaces for Giving Back”

---

FTSE4Good Index

---

PEOPLE’s “50 Companies That Care”

---

S&P 500 ESG Index

---



## Business Performance

FORTUNE 100

---

FORTUNE World’s Most Admired Companies

---

Pharma Reprtrak Most Reputable Companies

---

# Impact on economies

abbvie







Globally creating  
jobs and  
stimulating  
economies around  
the world

**~30,000**  
employees globally

**14,000+**  
employees in the U.S.

abbvie



# Spending benefits

Economic impact goes beyond medicine

**51k**

Suppliers globally


**\$13.3bn**

Spent with third parties globally

Suppliers in all  
**50 states**  
and the District of Columbia



abbvie



# 8 state-of-the-art research and development facilities



# 14 manufacturing centers



We make global impact.  
Our people and their passion  
create endless possibilities.



abbvie



People. Passion. Possibilities.®

**AbbVie.com**

[AbbVie.com/Responsibility](https://www.abbvie.com/Responsibility)

abbvie

US-ABBV-190274  
CM-0103-0619